But why is there a risk
NICE recommends new drug for people living with obesity (semaglutide)
Diabetes Obes Metab 12:532539 Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, Yamaguchi M, Tanabe H, Kimura-Someya T, Shirouzu M, Ogata H, Tokuyama K, Ueki K, Nagano T, Tanaka A, Yokoyama S, Kadowaki T (2013) A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity
Compounded GLP-1s Compounded GLP-1s can expand access to treatment under several different circumstances, including when theres a drug shortage, if a dosage is needed that isnt commercially available, or if you have an allergy to one of the ingredients
Consider your medical history BMI and Comorbidities: GLP-1 agonists: Weight loss medications are an approved treatment for people with a Body Mass Index (BMI) over 30, or a BMI over 27 with at least one comorbidity like type 2 diabetes, hypertension or sleep apnea